Clonal heterogeneity in differentiation response and resistance to the IDH2 inhibitor enasidenib in acute myeloid leukemia - Quek, L; David, M; Kennedy, A; Metzner, M; Amatangelo, M; Shih, A; Stoilova, B; Karamitros, D; Quivoron, C; Heiblig, M; Willekens, C; Saada, V; et al. (American Society of Hematology, 2017)